Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1810 • ACR Convergence 2024
Modulation of Type I Interferon Signaling by Anifrolumab Alters the Spatial Immune Landscape in Cutaneous Lupus Erythematosus
Ksenia Anufrieva¹, Rochelle Castillo², Ce Gao², Jessica Liu², Neda Shahriari², Kimberly Hashemi², Dustin Taylor³, Rachael Rowley², Elizabeth Rainone², Avery LaChance², Rachel Gate⁴, ilya Korsunsky², Ruth Ann Vleugels⁵ and Kevin Wei⁶, ¹BWH, Cambridge, MA, ²Brigham and Women's Hospital, Boston, MA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴10x Genomics, Pleasanton, CA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Reliable and effective treatments for refractory cutaneous lupus erythematosus (CLE) remained elusive until the arrival of anifrolumab, a monoclonal antibody targeting the type I…
Abstract Number: 1966 • ACR Convergence 2024
Comparison of a Dynamic Optical System with Physician Physical Assessment of PIP Joints of Systemic Lupus Erythematosus Patients
Wei Tang¹, Leila Khalili², Moegammad Bardien³, Alessandro Marone³, Chloe Gong², Xin Wang², Shane Murray², Stephen Kim³, Andreas Hielscher³, Laura Geraldino⁴ and Anca Askanase², ¹Westchester Medical Center, Valhalla, ²Columbia University Medical Center, New York, NY, ³Tandon School of Engineering New York University, New York, NY, ⁴Division of Rheumatology, Department of Medicine, Columbia University, New York, NY
Background/Purpose: Patients with SLE arthritis face chronic, disabling symptoms, and progressive joint damage. Arthritis/arthralgias is one of the most common symptoms of lupus. The heterogeneity…
Abstract Number: 2374 • ACR Convergence 2024
Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia
Omer Uludag¹, Sarvan Aghamuradov¹, Cansu Erel Gezegen², Marjan Jabbarli², Ismat Habibov², Ahmet Oguz Celik², Yasemin Yalcinkaya¹, Ahmet Gul¹, Murat Inanc¹ and Bahar Artim Esen¹, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey
Background/Purpose: Thrombocytopenia has been reported at frequencies ranging from 10 to 40 % in different cohorts. Treatment can be challenging and due to its considerable…
Abstract Number: 2392 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study
Güllü Sandal Uzun¹ and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) and idiopathic inflammatory myositis (IIM) are chronic, potentially severe autoimmune diseases, that may affect many organs/ systems. In this study, we…
Abstract Number: 2412 • ACR Convergence 2024
Validation of Proposals for Definitions of Moderate and Severe Disease Activity in Systemic Lupus Erythematosus, Based on Data Gathered from the RELESSER-PROS Register Database
Irene Altabás-González¹, Íñigo Rúa-Figueroa², Coral Mouriño³, Ivonne Lourdes Mamani⁴, Karen Roberts⁵, Julia Martínez-Barrio⁶, María Galindo-Izquierdo⁷, Jaime Calvo-Alen⁸, MARIA CELIA ERAUSQUIN ARRUABARRENA⁹, Belen Serrano-Benavente⁶, Irene Carrión-Barberà¹⁰, Esther Uriarte-Isacelaya¹¹, Eva Tomero Muriel¹², Mercedes Freire González¹³, Ricardo Blanco-Alonso¹⁴, Eva Salgado-Pérez¹⁵, Paloma Vela-Casasempere¹⁶, Antonio Fernández-Nebro¹⁷, Alejandro Olive¹⁸, Clara Sanguesa¹⁹, Javier Narvaez-García²⁰, Raúl Menor Almagro²¹, José Rosas-Gómez de Salazar²², José Ángel Hernández Beriain²³, Francisco j. Manero-Ruiz²⁴, Elena Aurrecoechea²⁵, Carlos Montilla²⁶, gema Bonilla²⁷, Oihane Ibarguengoitia Barrena²⁸, Vicenç Torrente-Segarra²⁹, Ana Paula Cacheda³⁰, María García-Villanueva³¹, Clara Moriano³², Loreto Horcada³³, Nuria Lozano-rivas³⁴, Cristina Bohorquez³⁵ and José María Pego-Reigosa³⁶, and RELESSER-Group, ¹Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, ²Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ³Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴COMPLEJO HOSPITALARIO UNIVERSITARIO DE VIGO, Pontevedra, Spain, ⁵Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital 12 de Octubre, Madrid, Madrid, Spain, ⁸Hospital Universitario de Araba, Araba, Spain, ⁹Gob Canarias, Tenerife, Canarias, Spain, ¹⁰Hospital del Mar, Barcelona, Spain, ¹¹Hospital Univeritario de Donostia, San Sebastián, Spain, ¹²La Princesa Hospital, Madrid, Madrid, Spain, ¹³Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ¹⁵Complejo Hospitalario de Orense, Ourense, Spain, ¹⁶Hospital General Universitario Alicante, Alicante, Spain, ¹⁷Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, ¹⁸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ²¹Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ²²Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ²³Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain, ²⁴H. Miguel Servet, Zaragoza, Spain, ²⁵Hospital de Sierrallana, Torrelavega, Spain, ²⁶Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ²⁷Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁸Rheumatology Division, Galdakao-Usansolo University Hospital, Galdako, Spain, ²⁹Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, ³⁰Hospital Universitario Son Llàtzer, Mallorca, Spain, ³¹Hospital Ramón y Cajal, MADRID, Madrid, Spain, ³²Hospital León, LEON, Spain, ³³Hospital Complex of Navarra, Pamplona, Spain, ³⁴Virgen de la Arrixaca University Hospital, Murcia, Spain, ³⁵Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, ³⁶Galicia Health Service (SERGAS), Vigo, Spain
Background/Purpose: In systemic lupus erythematosus (SLE), there is not a standardized and validated definition of states of moderate and severe SLE activity. The aim of…
Abstract Number: 2428 • ACR Convergence 2024
Vitamin-D Effect on SLE- Scoping Review
Joud Enabi¹, Rumeysa Ucar¹, Maneesh Mannem² and Sharafaldeen Bin Nafisah³, ¹TTUHSC, odessa, ²UMMC, Mississippi, ³KFMC, Riyadh, Saudi Arabia
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder primarily affecting women with diverse symptoms across multiple organs. Disease activity is assessed using tools like…
Abstract Number: 2556 • ACR Convergence 2024
A Multi-center Study of Associations Between Neighborhood-Level Child Opportunity, Initial Disease Severity and Acute Care Utilization Among Children with SLE
Joyce Chang¹, Jessica Liu¹, Emily Smitherman², Pooja Patel³, Gabrielle Alonzi¹, Gabrielle Morgan⁴, Livie Timmerman⁵, Laura Berbert⁶, Edie Weller¹, Karen Costenbader⁷ and Mary Beth Son⁸, ¹Boston Children's Hospital, Boston, MA, ²University of Alabama at Birmingham, Birmingham, AL, ³Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Alabama at Birmingham, Gardendale, AL, ⁶Boston Children's Hospital, Belmont, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁸Boston Children's Hospital, Brookline, MA
Background/Purpose: Child opportunity is defined as the neighborhood resources and conditions that promote healthy childhood development. We determined whether low neighborhood-level opportunity associates with more…
Abstract Number: 2625 • ACR Convergence 2024
Brain Injury Markers Correlate with Impaired Executive Function and Disease Activity in Children with Systemic Lupus Erythematosus
Oscar Mwizerwa¹, Justine Ledochowski², Tala El Tal³, Ganesh Ramanathan², Sarah Mossad⁴, Ibrahim Mohamed⁵, Joanna Law⁶, Lawrence Ng², Paris Moaf², Asha Jeyanathan¹, Adrienne Davis⁷, Ann Yeh², Linda Hiraki², Deborah Levy², Zahi Touma⁸, Joan Wither⁹, Busi Zapparoli¹⁰, Ashley Danguecan¹¹ and Andrea Knight¹², ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Brampton, ON, Canada, ⁶The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁷Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰The Hospital for Sick Children, Etobicoke, ON, Canada, ¹¹The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ¹²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) commonly experience impaired executive function (EF), and attribution to neuropsychiatric lupus (NPSLE) is challenging. Serum markers of…
Abstract Number: 0002 • ACR Convergence 2024
Preclinical Evaluation of BCMA And/or CD19 Nanobody-based Single or Compound CAR-T Cells Targeting B and Plasma Cells Associated with Autoimmune Disorders
Byeong Hyeok Choi¹, Vincent M DeStefano², Masayuki Wada², Kevin G Pinz¹, Greg Deener², Nabil Hagag¹, Ahmed Abdel-Razek¹, Yu Ma³, Jing Luo³ and Yupo Ma², ¹iCell Gene Therapeutics Inc., Stony Brook, NY, ²iCell Gene Therapeutics, Inc., Stony Brook, NY, ³iCar Bio Therapeutics Ltd, Zhongshan City, Guangdong, China (People's Republic)
Background/Purpose: CD19 single and BCMA-CD19 compound chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable activity against autoimmune disorders, although relapses with CD19 CAR…
Abstract Number: 0096 • ACR Convergence 2024
Simultaneous Contribution of Brain-Intrinsic and Peripheral Disease Mechanisms to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus (NPSLE)
Hadijat Makinde¹, Mohammad Khan¹, Cecilia Stumpf², Yidan Wang³, Tyler Therron², Margaret Goldman², Deborah Winter⁴ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Hanover Park, IL, ⁴Northwestern University, Skokie, IL
Background/Purpose: While NPSLE are among the least understood complications, increasing evidence points to microglia, a brain-resident innate immune cell population, as a driver of disease.…
Abstract Number: 0171 • ACR Convergence 2024
Associations Between Discrimination Experiences and Patient-Reported Outcomes Among Asian Individuals with Systemic Lupus Erythematosus (SLE)
Patti Katz¹, JoonSuk Park², Kamil Barbour³, Kurt Greenlund³, Maria Dall'Era⁴ and Jinoos Yazdany², ¹UCSF, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³CDC, Alpharetta, GA, ⁴UCSF, Corte Madera, CA
Background/Purpose: Discrimination experiences have been linked to poor outcomes among Black individuals with SLE.1 Among Asian adults in the general US population, discrimination has been…
Abstract Number: 0196 • ACR Convergence 2024
Associations Between Systemic Lupus Erythematosus (SLE) and the Social Vulnerability Index (SVI)
Zoe Reed¹, Xana Howard¹, Cristina Arriens¹, Teresa Aberle¹, Wade DeJager², Joan Merrill³ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects young women of certain racial and ethnic minority groups with enhanced severity…
Abstract Number: 0373 • ACR Convergence 2024
Enhancing Lupus Patient Education and Support at Kings County Hospital
Dmytro Gatsak¹, Jayashree Gandhi¹, Aleksander Feoktistov², Eugeniya Golub³ and Michael Trevisonno⁴, ¹Kings County Hospital/ SUNY Downstate Medical Center, Brooklyn, NY, ²Kings County Hospital Center/ H+H NYC, Brooklyn, NY, ³Kings County Hospital/ SUNY Downstate Medical Center, Staten Island, NY, ⁴State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Kings County Hospital, located in Brooklyn, New York, sees an estimated 243 patients with Systemic Lupus Erythematosus (SLE) annually. The patient demographic is predominantly…
Abstract Number: 0454 • ACR Convergence 2024
Evaluating the Rate of Cervical Cancer Screening and HPV Vaccination in Women with Systemic Lupus Erythematosus Within a Large Urban Healthcare System
Alana Haussmann¹, Eunice Adu Dapaah², John FitzGerald² and Maureen McMahon³, ¹University of California Los Angeles, Santa Monica, CA, ²UCLA, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Prior research has outlined an increased incidence of cervical dysplasia and cervical cancer in women diagnosed with systemic lupus erythematosus (SLE). These individuals face…
Abstract Number: 0622 • ACR Convergence 2024
Translation, Adaptation and Validation of the Brazilian-Portuguese Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) Version: Partial Results from a Single Centre
Clarice Mata Machado, Cristina Lanna, Juliana Garrido, Fabiana Moura and Rosa Telles, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: In recent years, several indices of disease activity in SLE have been proposed. The Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) showed a high…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.